Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VELCADE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    208 result(s) found for: VELCADE. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005819-26 Sponsor Protocol Number: 26866138-MMY-2036 Start Date*: 2006-05-19
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    10028228
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003077-25 Sponsor Protocol Number: VELCADE-MALT- LYMPHOM Start Date*: 2005-09-13
    Sponsor Name:AKH Vienna
    Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: patients with MALT-lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002756-18 Sponsor Protocol Number: NMSG 15/05 Start Date*: 2005-09-09
    Sponsor Name:Nordic Myeloma Study Group
    Full Title: Bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. A randomised NMSG trial (15/05)
    Medical condition: The main purpose of this trial is to study the effect of consolidation treatment with Velcade after autologous stem cell transplantation (ASCT) for multiple myeloma. At ASCT, patients will be rando...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IS (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000734-21 Sponsor Protocol Number: FL05-1 Start Date*: 2005-09-13
    Sponsor Name:Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Full Title: A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma
    Medical condition: Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001462-33 Sponsor Protocol Number: 26866138-MMY-2045 Start Date*: 2008-01-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone ...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) LT (Completed) HU (Completed) ES (Completed) GR (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001842-34 Sponsor Protocol Number: DOXIL-MMY-3001 Start Date*: 2004-11-29
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
    Medical condition: Recurred or relapsed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000952-28 Sponsor Protocol Number: 26866138-MMY-3021 Start Date*: 2008-12-17
    Sponsor Name:Janssen-Cilag International NV (JCI)
    Full Title: An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma
    Medical condition: The subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory d...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000293-62 Sponsor Protocol Number: GEM11-BENVELPRES Start Date*: 2011-05-04
    Sponsor Name:Fundación PETHEMA
    Full Title: Phase II, Open, National, Multicenter Study of Bendamustine, Bortezomib (Velcade) and prednisone (BVP) in patients with newly diagnosed multiple myeloma (BenVelPres)
    Medical condition: MULTIPLE MYELOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004648-29 Sponsor Protocol Number: C05002 Start Date*: 2005-05-09
    Sponsor Name:Janssen Cilag International, N.V. (Sponsor in European Union)
    Full Title: A Multicenter, Open-label, Phase 2 Study of VELCADE (bortezomib) for Injection in Previously Treated Patients with Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloa...
    Medical condition: Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar Features
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004420-39 Sponsor Protocol Number: 05-10 Start Date*: 2006-05-18
    Sponsor Name:All-Ireland Co-operative Oncology Research Group (ICORG)
    Full Title: An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADE (Bortezomib) in Patients with Malignant Pleural Mesothelioma
    Medical condition: Malignant Pleural Mesothelioma (in first line, and second line treatment settings)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed) BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-003357-27 Sponsor Protocol Number: 26866138-LUC-2001 Start Date*: 2006-03-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung ...
    Medical condition: Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004264-39 Sponsor Protocol Number: 26866138-MMY-2060 Start Date*: 2009-01-30
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease
    Medical condition: Myeloma related bone disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) AT (Completed) GB (Completed) SE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001628-35 Sponsor Protocol Number: X05140 Start Date*: 2006-01-31
    Sponsor Name:EBMT - CLWP
    Full Title: A randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing a...
    Medical condition: multiple myeloma patients in progression or relapse after autologous transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) CZ (Completed) AT (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003174-27 Sponsor Protocol Number: RC13-0284 Start Date*: 2014-06-12
    Sponsor Name:CHU de Nantes
    Full Title: A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TR...
    Medical condition: Young untreated patients with Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-003936-38 Sponsor Protocol Number: R08096M Start Date*: 2008-08-29
    Sponsor Name:TAYS, Hematologian yksikkö
    Full Title: Bortetsomibi + Dexametasonihoidon hoitovasteen laadun selvitys aiemmin hoitamattomilla myeloomapotilailla.
    Medical condition: Multippeli myelooma, aiemmin hoitamattomat potilaat
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003791-37 Sponsor Protocol Number: KFE2011.06 Start Date*: 2011-09-30
    Sponsor Name:Department of Haematology, Aalborg University Hospital
    Full Title: Pre-Clinical Phase 0 Microdose Study to evaluate the effect of Melphalan, Bortezomib and Dexamethasone on cellular gene-expression.
    Medical condition: Multiple Myelomatosis (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10028569 Myelomatosis multiple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-007022-64 Sponsor Protocol Number: NMSG 16/07 Start Date*: 2007-03-06
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of bortezomib-dexametason and high-dose melphalan in patients relapsing after high-dose melphalan with autologous stem cell support
    Medical condition: Patients with multiple myeloma earlier treated with high-dose melphalan with autologous stem cell support experiencing their first relapse.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005777-30 Sponsor Protocol Number: 26866138-LYM-3001 Start Date*: 2006-03-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma
    Medical condition: Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025320
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SK (Completed) ES (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:07:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA